23:45 , Apr 16, 2019 |  BC Extra  |  Company News

Achaogen files for bankruptcy amid continued headwinds for antibiotic developers

Following regulatory headwinds and what it called very limited uptake of its sole marketed antibiotic, Achaogen filed for Chapter 11 bankruptcy late Monday. It is one of several antibiotic companies that have lost over half...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:22 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

FDA approves Paratek antibiotics

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Oct. 2 for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure...
23:45 , Oct 2, 2018 |  BC Extra  |  Company News

FDA approves Paratek antibiotics

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Tuesday for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections...
19:18 , Sep 14, 2018 |  BioCentury  |  Finance

Zai shores up

As Zai Lab Ltd. (NASDAQ:ZLAB) prepares for its first product launch, more clinical work and additional deals to fortify its pipeline, the company passed on the chance to list on Hong Kong’s new biotech chapter,...
16:28 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

FDA panel votes in favor of Paratek's antibiotic

FDA's Antimicrobial Drugs Advisory Committee voted in favor of IV and oral formulations of omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The amniomethylcycline antibiotic's PDUFA date is in early October. The panel voted that there is...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
17:57 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

FDA panel to review Paratek antibiotic

FDA's Antimicrobial Drugs Advisory Committee scheduled an Aug. 8 meeting to discuss two NDAs for omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The agency is reviewing oral and IV versions of the amniomethylcycline antibiotic to treat...
19:50 , Jun 20, 2018 |  BC Extra  |  Company News

FDA panel to review Paratek antibiotic

FDA's Antimicrobial Drugs Advisory Committee has scheduled an Aug. 8 meeting to discuss two NDAs for omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The agency is reviewing oral and IV versions of the amniomethylcycline antibiotic to...